Home
  1. Grima DT, Goodman SG, Leiter LA, Attard CL, Chow CM, Langer A. How Many Cardiovascular Events Could be Prevented With Optimal Management of High Risk Canadians? Can J Cardiol. 2008 May;24(5):363-8.

  2. Grima DT, Papaioannou A, Thompson MF, Pasquale MK, Adachi JD. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis. Osteoporos Int. 2008 May;19(5):687-97.

  3. Churchill DN, Macarios D, Attard C, Kallich J, Goeree R. Costs associated with erythropoiesis-stimulating agent administration to hemodialysis patients. Nephron Clin Pract. 2007;106(4):c193-8.

  4. Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and type 2 diabetes in Canada. Pharmacoeconomics. 2007;25(3):253-266.

  5. Althin R, Grima DT, Dhawan R, Bernard LM. Considerations in developing model-based economic evaluations of glaucoma treatment. J Glaucoma. 2006;15:541-547.

  6. Kohli M, Attard C, Lam A, Huse D, Cook J, Bourgault C, Alemao E, Yin D, Marentette M. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. Pharmacoeconomics. 2006;24(8):815-30.

  7. Black DM, Palermo L, Grima DT. Developing better economic models of osteoporosis: considerations for the calculation of the relative risk of fracture. Value in Health 2006; 9(1): 54-8. In December 2006, this article was ranked as number 13 on the most read articles in Value in Health.

  8. Thompson M, Gawel M, Desjardins B, Ferko N, Grima D. An economic evaluation of rizatriptan in the treatment of migraine. Pharmacoeconomics 2005;23(8):837-50.

  9. Tingey D, Bernard LM, Grima DT, Miller B, Lam A. Intraocular pressure control and persistence on treatment in glaucoma and ocular hypertension. Cdn J Ophthalmol. 2005 Apr;40(2):161-9.

  10. Goldie SJ, Kohli M, Grima DT, Weinstein MC, Wright TC, Bosch FX, Franco EL. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004 Apr 21;96(8):604-15.

  11. Hershorn S, Becker DL, Miller E, Thompson M, Forte L. Impact of a health education intervention in overactive bladder patients. Can J Urol. 2004 Dec;11(6):2430-7.

  12. Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA, Weinstein MC. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang. 2004 Jan;86(1):28-40.

  13. McDonald H, Hux M, Brisson M, Bernard L, Nickel JC. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. Can J Urol. 2004;11(4):2327-40.

  14. Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers. Ostomy Wound Manage. 2003 Nov;49(11):76-84.

  15. Bernard LM, Grima DT, Lam LA, Abellea S, Martin M, Dhawan R, Althin R. Clinical and economic impacts of latanoprost 0.005% in the first-line treatment of open-angle glaucoma and ocular hypertension in France. European Journal of Ophthalmology 2003, Jul;13 Suppl 4:S30-43.

  16. Goldie SJ, Grima DT, Kohli M, Wright TC, Weinstein MC, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer. 2003 Oct 10;106(6):896-904.

  17. Torrance GT, Grima DT. Demonstrating value for money of biopharmaceuticals: Health economics, regulation and reimbursement worldwide. Biotechnology Focus Magazine. Oct 2003.

  18. Attard C, Kohli M, Coleman S, Bradley C, Hux M, Atanackovic G, Torrance GW. The burden of illness of severe nausea and vomiting of pregnancy in the United States. Am J Obstet Gynecol. 2002 May;186(5 Suppl Understanding):S220-7.

  19. Grima DT, Burge RT, Becker DL, Tosteson ANA. Short-term cost effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture. P&T 2002; 27(9);448-455.

  20. Tosteson ANA., Jönsson B, Grima DT, O’Brien BJ, Black DM, Adachi JD. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporosis Int. 2001;12(10):849-57.

  21. Marshall JK, Pellissier JM, Attard CL, Kong SX, Marentette MA. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. Pharmacoeconomics. 2001;19(10):1039-49.

  22. O'Brien BJ, Goeree R, Bernard L, Rosner A, Williamson T. Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. Clin Ther. 2001;23(12):2038-49.

  23. Koren G, Magee L, Attard C, Kohli M, Atanackovic G, Bishai R, Chandra K, Navioz Y, Maltepe C. A novel method for the evaluation of the severity of nausea and vomiting of pregnancy. Eur J Obstet Gynecol Reprod Biol. 2001 Jan;94(1):31-6.

  24. Sibbald RG, Torrance GW, Walker V, Attard C, MacNeil P. Cost-effectiveness of Apligraf in the treatment of venous leg ulcers. Ostomy Wound Manage. 2001 Aug;47(8):36-46.

  25. Grima DT, Torrance GW, Francis G, Rice G, Rosner A, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler. 2000 Apr;6(2):91-8.

  26. Rosner AJ, Grima DT, Torrance GW, Bradley C, Adachi JD, Sebaldt RJ, Willison DJ. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics. 1998 Nov;14(5):559-73.

  27. Chiba N, Bernard L, O’Brien B, Goeree R, Hunt. A Canadian physician survey of dyspepsia management. Can J of Gastroenterol 1998;12(1):83-90.

  28. Hotchkies L, Grima DT, Hedayati S. The total process cost of parenteral antibiotic therapy: beyond drug acquisition cost. Clinical Therapeutics. 1996; 18 (4):716-725.

  29. Coyte PC, Hawker G, Croxford R, Attard C, Wright JG. Variation in rheumatologists' and family physicians' perceptions of the indications for and outcomes of knee replacement surgery. J Rheumatol. 1996 Apr;23(4):730-8.